EGFR and non-small cell lung carcinoma: The phase III clinical trial CheckMate 057 confirmed (33) that patients with advanced NSCLC who were treated with nivolumab survived longer than those treated with docetaxel during or after platinum-based chemotherapy, and it was reported for the first time that ICIs did not improve PFS or overall survival (OS) in NSCLC patients with EGFR mutations.